GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

31

Multinational EBRT Data Support Curative-Intent Role in Early HCC : J Clin Oncol | May 2026

Introduction External Beam Radiation Therapy has historically played a limited role in the management of Hepatocellular Carcinoma because of concerns regarding hepatic toxicity and limited survival data. However,...

32

Sintilimab–Lenvatinib Enables Conversion Surgery in Advanced HCC : Signal Transduct Target Ther | May 2026

Introduction Most patients with Hepatocellular Carcinoma present with advanced unresectable disease, limiting curative-intent treatment opportunities. Although systemic therapy remains the standard for advanced-stage HCC, modern immunotherapy-based combinations have...

33

Real-World STRIDE Validates Survival Benefit in Advanced HCC : JHEP Report | Mar 2026

Introduction Durvalumab plus Tremelimumab (STRIDE regimen) has emerged as a first-line immunotherapy option for unresectable Hepatocellular Carcinoma following the pivotal HIMALAYA trial. However, real-world evidence regarding efficacy, safety...

34

FAP CAR-T Therapy Emerges as a Novel Antifibrotic Strategy in Liver Disease : JHEP Report | May 2026

Introduction Chimeric antigen receptor T-cell therapy has revolutionized hematologic oncology and is increasingly being explored beyond cancer. In chronic liver disease, progressive fibrosis driven by activated hepatic stellate...

35

Propranolol Adds No Benefit to Band Ligation in HCC-Related Variceal Bleeding | Gut

Introduction Secondary prevention of oesophageal variceal bleeding traditionally relies on combination therapy with non-selective beta-blockers and endoscopic band ligation in patients with cirrhosis. However, patients with hepatocellular carcinoma...

36

Biomarkers in HCC Surveillance: Gastroenterology | May 2026

Introduction and Summary This commentary discusses the role of serum biomarkers in hepatocellular carcinoma surveillance, particularly after a randomised trial by Hirode et al. evaluated whether adding AFP,...

37

AGA Guidelines on HCC Surveillance: Gastroenterology | May 2026

Introduction Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality in patients with cirrhosis. Despite advances in treatment, outcomes are largely determined by stage at diagnosis, making...

38

HCC with PVTT: Liver Cancer | April 2026

Introduction Hepatocellular carcinoma with portal vein tumor thrombus represents one of the most aggressive forms of liver cancer, associated with poor prognosis and limited survival. Standard treatment relies...

39

Nutrition in MASLD: Frontline Gastroenterology | 2026

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease worldwide and closely parallels the epidemics of obesity and type 2 diabetes....

40

Adjuvant Immunotherapy in HCC: JGH | March 2026

Introduction Hepatocellular carcinoma remains a major global cancer burden, with high recurrence rates even after curative therapies such as resection or ablation. Historically, effective adjuvant treatments have been...

Previous
13458
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer